Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HCW9302, an IL-2 fusion protein · 1 trial · 1 indication
Evaluate the safety profile of HCW9302 monotherapy in subjects with Alopecia Areata (AA), based on the incidence, type, and severity of adverse events (AEs) classified according to MedDRA.
| Arm | Type | Description |
|---|---|---|
| Study of HCW9302, an IL-2 fusion protein, for alopecia areata | EXPERIMENTAL | Single dose subcutaneous injection of HCW9302. |
| Name | Type | Description |
|---|---|---|
| HCW9302, an IL-2 fusion protein | DRUG | Injection |
Inclusion Criteria: 1. Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent. 2. Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening. 3. Negative serum pregnancy test within 14 d...
HCW9302 is an investigational IL-2 fusion protein being developed for the treatment of alopecia areata (AA), a dermatologic condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
HCW9302 targets IL-2, a cytokine involved in immune regulation. As an IL-2 fusion protein, it is designed to modulate immune responses relevant to alopecia areata. The drug is being studied for its potential therapeutic effect in this condition.
HCW9302 is being developed by HCW Biologics Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for alopecia areata.
HCW9302 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety and tolerability.
HCW9302 is being studied in a Phase 1 clinical trial with the identifier NCT07049328. This trial, titled 'HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata,' is recruiting 30 participants in the United States. The study is open to adults aged 18 years and older.